Revive Therapeutics (RVV.V) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19.
Today, Revive Therapeutics announced that it has submitted a Type C meeting request package to the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long-term COVID. Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.
The backstory: On July 6, 2023, Revive announced findings that would make any investor’s ears perk up. In their study for using bucillamine against mild to moderate COVID-19, they found zero deaths and fewer hospitalizations in the Bucillamine-treated groups compared to placebo, especially at higher doses. If that’s not enough to raise eyebrows, consider this—patients with oxygen levels in the danger zone saw significant improvements, a beacon of hope for those gasping in the shadow of long COVID.
The US CDC estimates 7.5% of U.S. adults are haunted by long covid, with as much as 20% of the workforce having dealt with it since the pandemic, but without an accurate way to diagnose sufferers, much of that population will go untreated and show itself in vastly larger rates of depressed productivity, employee churn,. and increased healthcare costs.
And with economic costs of long Covid potentially spiraling to a staggering $3.7 trillion in the US alone, according to Harvard’s David Cutler, PhD, the stakes couldn’t be higher.
Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID. The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed Phase 2 clinical study for long COVID to present to the FDA.
The stock is up 20% on this news at time of writing.
The stock remains in its consolidation phase. The stock should see buyers enter here to hold support. A daily close above $0.04 would be a good start for potential upwards momentum. The major resistance zone comes in at the $0.06 zone.
